Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
Recruiting now · Early Phase 1
Conditions studied: Eyelid Dermatitis
In brief
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Key facts
- Study ID
- NCT06684522
- Run by
- Northwestern University
- People needed
- 10
- Starts
- 2025-12-18
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2026-05-26
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Individuals age 18-70 years old with eyelid dermatitis for at least two months
- Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib)
- Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib.
- Willing and able participants that provide informed consent
- Willing and able participants that comply with study activities
You may not qualify if…
- Self-reported history of allergic response to upadacitinib
- Subject with self-reported history of heart disease, stroke, or neurological conditions
- Currently taking topical medications for eyelid dermatitis within one week of starting study drug
- Women who are pregnant, nursing, or who may become pregnant during the study
- Non-English-speaking subjects
- Patients with an active serious infection
- Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment.
- Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb<8g/dL, ALC<500 cells/mm3 and ANC <1000 cells/mm3
- Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.
Where it is running
- Northwestern University Department of Dermatology — Chicago, Illinois, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.